f new advanced sequencing molecular tests to diagnose various clinically relevant genetic causes of muscular dystrophies and myopathies in adults and children. These tests help avoid painful muscle biopsies that, in the past, were the means to diagnose patients with muscle weakness. The company launched advanced sequencing molecular tests to test for various genetic causes of rare, progressive movement disorders called hereditary ataxias, which affect movement of the legs and hands, and speech and eye movements. The company also launched advanced sequencing molecular tests to test for various genetic causes of rare, progressive movement disorders called hereditary spastic paraplegias, which are characterized by a slowly progressive stiffness and weakness of the legs. The diagnosis guides physicians in the use of medications to reduce muscle tightness. Oncology The company introduced LeukoVantage, a genomic test service that aids in the diagnosis, prognosis monitoring and selection of treatment for myeloid neoplasms, a group of hematologic malignancies that include acute myeloid leukemia. The company introduced access to a companion test service for a new anti-PD-1 therapy for metastatic non-small cell lung cancer developed by Merck and a complementary test service for a new anti-PD-1 therapy for metastatic non-small cell lung cancer developed by Bristol-Myers Squibb. The company introduced a prognostic panel, including new probes to aid physicians in treating patients with plasma cell myeloma. Prescription Drug Monitoring and Toxicology The company introduced a quantitative test for buprenorphine and naloxone. Patients treated with buprenorphine-naloxone co-formulation would demonstrate both naloxone and buprenorphine/norbuprenorphine drug analysis. Naloxone is not detected with buprenorphine-only use. Sports Science and Human Performance The company conducted beta programs at select elite endurance events using the Blueprint for Athletes service to empower athletes to track their progress from the onset of training through the event. Women’s and Reproductive Health The company introduced QNatal Advanced, a new noninvasive prenatal screening service for detecting chromosomal abnormalities in certain high-risk pregnancies. The company improved its HPV offerings with five new tests. One assay is used in connection with cytology to assess the presence or absence of high risk HPV genotypes 16, 18 and/or 45. This information together with physician's assessment of cytology history, other risk factors and professional guidelines might be used to guide patient treatment. The second assay is used in conjunction with cytology to evaluate anal dysplasia. The other three are used in combination with cytology, cytology history and other risk factors in aiding the diagnosis of vaginal cancer. Customers The company provides diagnostic information services to a range of customers, including managed care organizations and other health insurance providers; clinicians; hospitals; ACOs and IDNs; employers; patients; emerging retail healthcare providers; and other laboratories and other customers. Strategy The company’s strategy is to restore growth; drive operational excellence; simplify the organization; refocus on diagnostic information services; and deliver disciplined capital deployment. Regulation The company’s businesses are subject to or impacted by extensive and frequently changing laws and regulations in the United States (at both the federal and state levels) and the other jurisdictions in which the company conducts business, including some particular to its business and others relating to conducting business generally (export controls laws and the U.S. Foreign Corrupt Practices Act). The company’s diagnostic products business is subject to regulation by the FDA, as well as by foreign governmental agencies, under laws and regulations that govern the development, testing, manufacturing, labeling, advertising, marketing, distribution and post-market surveillance of diagnostic products. The company is subject to laws and regulations regarding protecting the security and p
quest diagnostics inc (DGX:New York)
3 Giralda Farms
Madison, NJ 07940
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|Cerner Corp||$55.61 USD||+0.33|
|Hologic Inc||$34.41 USD||0.00|
|Laboratory Corp of America Holdings||$127.95 USD||-0.06|
|Roper Technologies Inc||$171.08 USD||-0.92|
|View Industry Companies|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact QUEST DIAGNOSTICS INC, please visit www.questdiagnostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.